NICE u-turn backs Takeda’s Adcetris for sALCL

29th August 2017 Uncategorised 0

Takeda’s Adcetris has now been backed by the National Institute for Health and Care Excellence as an option to treat systemic anaplastic large cell lymphoma (sALCL), a very rare and aggressive cancer of the lymphatic system, on the NHS in England and Wales.

More: NICE u-turn backs Takeda’s Adcetris for sALCL
Source: News